OncLive TV

Geoffrey Shouse, DO, PhD, discusses currently available targeted therapies for the management of follicular lymphoma.

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept dose levels in patients with low-risk myelodysplastic syndrome who require red blood cell transfusions.

Karyn A. Goodman, MD, MS, discusses the use of chemoradiation after adjuvant chemotherapy in resected adenocarcinomas of the pancreatic head.

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

Michel Ducreux, MD, PhD, discusses findings from the TRANSMET trial of chemotherapy plus liver transplantation in unresectable colorectal liver metastases.

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.

Amrita Krishnan, MD, discusses the evolving role of belantamab mafodotin in the treatment of multiple myeloma.

Rita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma.

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Rom S. Leidner, MD, discusses data for DPV-001 combined with PD-1inhibition with or without a GITR agonist in advanced or metastatic HNSCC.

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Shannon Westin, MD, MPH, FACOG, discusses the FDA approval of durvalumab plus chemotherapy in dMMR advanced or recurrent endometrial cancer.

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Rory Shallis, MD, discusses the utility of luspatercept in the context of the phase 3 ELEMENT-MDS trial for patients with myelodysplastic syndrome.

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Ciara Kelly, MBBCh, BAO, discusses how the heterogeneity of GIST affects treatment decisions and the importance of testing for genetic abnormalities.

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Erika P. Hamilton, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-low breast cancer.

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.